Safety, Efficacy and Ethical Issues Regarding Weight-Loss Medications

Michael William Lee

Disclosures

Expert Rev Clin Pharmacol. 2009;2(2):111-113. 

In This Article

Introduction

In October 2008, two promising obesity treatments were essentially eliminated from future clinical application. Merck & Co., Inc. announced that the clinical development of taranabant was halted due to an unfavorable safety profile.[101] Approximately 3 weeks later, the Committee for Medicinal Products for Human Use (CHMP) of the EMEA concluded that the benefits of rimonabant (Acomplia®) no longer outweigh its risks, and recommended the suspension of the marketing authorization of Acomplia.[102] Thus, orlistat and sibutramine are the only remaining medications approved for the long-term treatment of obesity. Given that the WHO estimates that there are currently over 300 million obese adults worldwide,[103] the need for additional pharmacologic options remains unfulfilled. What safety, efficacy and ethical issues need to be addressed to order to improve such an unsatisfactory situation?

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....